All In Biotech

Drug Trial Radar · NCT06815627

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 18, 2025

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
Trust Bio-sonics, Inc.Industry
Sponsor type
Industry
Collaborators
CMIC ASIA-PACIFIC, PTE. LTD., TAIWAN BRANCH
First posted
Feb 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, prospective, open-label, multicenter study to assess the efficacy of NH002-enhanced echocardiography in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the left ventricular endocardial border delineation compared with unenhanced echocardiography. The study also aims to investigate the safety and tolerability of NH002.

Conditions

  • Cardiac Diseases

Interventions

  • NH002 (Perflutren Lipid Microspheres) Injectable SuspensionDrug

    NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Left Ventricular Endocardial Border Delineation (LVEBD)Time frame: Image data obtained pre-injection and within 10 minutes post-injection
  2. Left Ventricular Opacification (LVO)Time frame: Image data obtained pre-injection and within 10 minutes post-injection

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Keelung Chang Gung Memorial Hospital & Lovers Lake Branch

    Keelung, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • MacKay Memorial Hospital

    Taipei, Taiwan

  • Cathay General Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • National Taiwan University Hospital Hsin-Chu Branch

    Zhubei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.